

AMENDMENTS

In the claims:

Please cancel claims 17 and 33.

Please amend the claims as follows:

1-14 (withdrawn)

¹ ~~15~~ (currently amended) An anti-PSCA monoclonal antibody that inhibits the growth of PSCA-expressing cancer cells in vivo, wherein the antibody internalizes upon binding to PSCA on the cancer cell, the antibody being produced by a hybridoma selected from the group of hybridomas having ATCC accession number PTA-717, PTA-718, PTA-719, PTA-720, PTA-880, or PTA-2265.

16-17 (canceled)

³ ~~18~~ (currently amended) The antibody of claim ² ~~17~~ which is produced in bacteria.

² ~~19~~ (currently amended) The antibody of claim 15, which An anti-PSCA monoclonal antibody that inhibits the growth of PSCA-expressing cancer cells in vivo, wherein the antibody internalizes upon binding to PSCA on the cancer cell, and wherein the antibody is a humanized form of an anti-PSCA antibody produced by a hybridoma selected from the group of hybridomas having ATCC accession number PTA-717, PTA-718, PTA-719, PTA-720, PTA-880, or PTA-2265.

⁴ ~~20~~ (currently amended) The antibody of claim ¹ ~~15~~ ² or claim 19, wherein the cancer cells are from a cancer selected from the group consisting of prostate cancer, bladder cancer and lung cancer.

⁵ ~~21~~ (original) The antibody of claim 20, wherein the cancer is prostate cancer.

22-28 (withdrawn)

⁶ ~~29~~ (currently amended) A composition comprising the antibody of claim ¹ ~~15~~ or claim 19, and a carrier.

⁷ ~~30~~ (original) The composition of claim ⁶ ~~29~~, wherein the antibody is conjugated to a cytotoxic agent.

⁸ ~~31~~ (original) The composition of claim ⁷ ~~30~~, wherein the cytotoxic agent is a maytansinoid.

⁶
9 ~~32~~. (currently amended) The composition of claim ~~28~~⁶, wherein the carrier is a pharmaceutical carrier.

33 (canceled)

34-57 (withdrawn)
